Stacey M. Fernandes

Broad Institute — United States

Medicine · Health Sciences

30h-index6.6kcitations236works3.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(197), Immunodeficiency and Autoimmune Disorders(46), Lymphoma Diagnosis and Treatment(37), Acute Lymphoblastic Leukemia research(34), Glycosylation and Glycoproteins Research(24)

Publications236 total

Supplementary Figures S1-8 from METTL3-Mediated m<sup>6</sup>A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL
2025Open Access
Supplementary Tables S1-5 from METTL3-Mediated m<sup>6</sup>A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL
2025Open Access
Multi-proteomic analyses provide evidence for origin of a co-existing serum monoclonal gammopathy in CLL/MBL
Blood·2025Open Access
Nodal progression in CLL: Real-world predictors of richter transformation and identification of a distinct high-risk NP-CLL subgroup
Blood·2025Open Access
Characterization of IGHV subgroups and their prognostic relevance in CLL
Blood·2025Open Access
Acquisition of CLL-like epigenetic and transcriptomic states in low-count MBL
Blood·2025Open Access
SF3B1 mutations are associated with shorter time to first treatment in chronic lymphocytic leukemia
Blood·2025
Rare germline variant in NFATC4 associated with familial CLL
Leukemia·2025
Mutations and translocations associated with venetoclax resistance in chronic lymphocytic leukemia
Leukemia·2025
Novel PI3kδ inhibitor roginolisib synergizes with venetoclax in hematologic malignancies
Haematologica·2025· 2 citedOpen Access
Hyperinsulinemia-induced upregulation of adipocyte TPH2 contributes to peripheral serotonin production, metabolic dysfunction, and obesity
Journal of Clinical Investigation·2025· 3 citedOpen Access
Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia
Blood Advances·2025· 7 citedOpen Access
Erratum: Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease
Journal of Clinical Oncology·2025
BCL-2 dependence is a favorable predictive marker of response to therapy for chronic lymphocytic leukemia
Molecular Cancer·2025· 6 citedOpen Access
Chronic lymphocytic leukemia often arises by a multiclonal selection process
Haematologica·2025· 2 citedOpen Access
How close is autophagy-targeting therapy for Alzheimer's disease to clinical use? A summary of autophagy modulators in clinical studies
Frontiers in Cell and Developmental Biology·2025· 9 citedOpen Access
Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease
Journal of Clinical Oncology·2024· 29 citedOpen Access
Investigating the influence of germline <i>ATM</i> variants in chronic lymphocytic leukemia on cancer vulnerability
Haematologica·2024· 1 citedOpen Access
Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease
Blood·2024Open Access
Complex Karyotype, but Not Isolated <i>TP53</i> mutation, Predicts Overall Survival in Chronic Lymphocytic Leukemia Patients in the Era of Targeted Therapy
Blood·2024· 1 cited
page 1 of 12Next →

Frequent Co-authors

Jennifer R. Brown(43), Gad Getz(15), Matthew S. Davids(15), Catherine J. Wu(14), Donna Neuberg(13), Siddha Kasar(10), Laura Z. Rassenti(10), Thomas J. Kipps(10), Svitlana Tyekucheva(9), Bethany Tesar(7), Ignaty Leshchiner(7), David C. Fisher(7), Lili Wang(6), Stacey Gabriel(6), Benjamin L. Lampson(6), Philippe Armand(6), Kristen E. Stevenson(5), Carrie Sougnez(5), Wandi Zhang(5), Kenneth J. Livak(5)